Skip Navigation

An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib RP6530, a novel PI3K ?/? dual inhibitor given in combination with a histone deacetylase HDAC inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03770000

Study #:
STUDY00144274

Start Date:
Dec 23, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03770000

View Complete Trial Details & Eligibility at ClinicalTrials.gov